BCI-215

• Description :

  BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Phosphatase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bci-215.html

• Purity :

  99.86

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  O=C1/C(C(NC2CCCCC2)C3=C1C=CC(Br)=C3)=C/C4=CC=CC=C4

• Molecular Formula :

  C22H22BrNO

• Molecular Weight :

  396.32

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15 (10) :1436-45.|[2]Kaltenmeier CT, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther. 2017 Apr;361 (1) :39-50.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1245792-67-9]